Skye Bioscience, INC Form 4 insider transactions

Puneet S. Arora, Chief Medical Officer of Skye Bioscience, Inc., was granted stock options for 38,000 shares on February 24, 2025.

Skye Bioscience's Chief Development Officer, Tuan Tu Diep, sold shares to cover tax obligations related to vesting restricted stock units.

Skye Bioscience's Chief Financial Officer, Kaitlyn Arsenault, sold a total of 43,396 shares of common stock to cover tax obligations related to vesting of restricted stock units.

Skye Bioscience CEO, Punit Dhillon, sold shares to cover tax obligations related to vesting of performance-based restricted stock units.

A Skye Bioscience director, Paul A. Grayson, sold shares to cover tax obligations related to the vesting of performance-based restricted stock units.

Tuan Tu Diep, Chief Development Officer of Skye Bioscience, Inc., was granted stock options on October 28, 2024.

Kaitlyn Arsenault, CFO of Skye Bioscience, acquired stock options for 125,000 shares on October 28, 2024.

Skye Bioscience CEO Punit Dhillon was granted stock options to purchase 650,000 shares of common stock at an exercise price of $5.15, vesting monthly over four years.

Director Andrew J. Schwab acquired 70,000 stock options in Skye Bioscience, Inc. on October 28, 2024.

Paul A. Grayson, a director of Skye Bioscience, Inc., acquired 70,000 stock options on October 28, 2024, according to a recent SEC filing.

Karen L. Smith, a director of Skye Bioscience, Inc., was granted stock options to purchase 70,000 shares of common stock.

Director Deborah H. Charych acquired stock options for 70,000 shares of Skye Bioscience, Inc. on October 28, 2024.

Director Annalisa Jenkins acquired stock options in Skye Bioscience, Inc. on October 28, 2024.

Director Andrew J. Schwab reports the sale of Skye Bioscience (SKYE) common stock through affiliated entities, 5AM Ventures, in multiple transactions.

5AM Partners and related entities have sold shares of Skye Bioscience (SKYE) at prices ranging from $6.05 to $6.60, according to a recent SEC Form 4 filing.

Puneet S. Arora, Chief Medical Officer of Skye Bioscience, Inc., was granted stock options for 225,000 shares on September 3, 2024.

CEO of Skye Bioscience, Punit Dhillon, reports acquisition and disposal of common stock, including shares received from a pro rata distribution and shares held in a family trust.

Karen L. Smith, a director of Skye Bioscience, Inc., was granted stock options to purchase 40,000 shares of common stock on July 2, 2024.

5AM Partners and related entities significantly increased their stake in Skye Bioscience through a recent transaction.

Director Andrew J. Schwab reports the acquisition of 450,000 shares of Skye Bioscience, Inc. common stock through indirect holdings.

Director Grayson of Skye Bioscience, Inc. reports acquisition of stock options and restricted stock units tied to market capitalization and stock price milestones.

Director Deborah H. Charych acquired 35,000 stock options in Skye Bioscience, Inc. on February 29, 2024.

Director Annalisa Jenkins acquired stock options in Skye Bioscience, Inc. on February 29, 2024.

Director Andrew J. Schwab reports receiving a stock option grant for 35,000 shares of Skye Bioscience, Inc.

Director Margaret Dalesandro acquired 35,000 stock options in Skye Bioscience, Inc. on February 29, 2024.

Keith Wayne Ward, a director at Skye Bioscience, Inc., acquired 35,000 stock options on February 29, 2024, exercisable at $14.56 per share.

Director Praveen Tyle of Skye Bioscience, Inc. was granted stock options to purchase 35,000 shares of common stock on February 29, 2024.

Tuan Tu Diep, Chief Development Officer of Skye Bioscience, was granted stock options and restricted stock units (RSUs) tied to market capitalization and stock price milestones.

Kaitlyn Arsenault, CFO of Skye Bioscience, reports the acquisition of stock options and restricted stock units (RSUs) based on specific market capitalization and stock price milestones.

Punit Dhillon, CEO of Skye Bioscience, was granted stock options and restricted stock units (RSUs) tied to market capitalization and stock price milestones.